Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

The PATCH study will continue to accrue patients in the UK

The Prostate Adenocarcinoma: TransCutaneous Hormones or PATCH trial is an ongoing study in the UK that was designed (in a series of stages) to determine whether estrogen patch therapy might be at least no worse than (i.e., “non-inferior” to) LHRH agonist therapy in suppressing androgens to castrate level. … READ MORE …

What’s being presented at ASCO this year: II

A “first-of-its kind” quality of life study to be presented at ASCO this year is a year-long, randomized, three-arm trial of the value of “purposeful” physical exercise in the management of men on androgen deprivation therapy (ADT) for progressive prostate cancer. … READ MORE …

Deferred or immediate initiation of ADT in patients with PSA-only relapse

Abstracts of all papers to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) were made available for pre-meeting review yesterday. A paper on the appropriate timing of initiation of androgen deprivation therapy (ADT) was featured by ASCO in its related news conference. … READ MORE …

Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

Memory, thinking, concentration, and ADT for prostate cancer

An ongoing study, funded by the American Cancer Society, has been approved by the Mount Sinai Institutional Review Board here in the USA, and relates specifically to men receiving androgen deprivation therapy (ADT, also known as “hormone” therapy) for prostate cancer. It may be of particular interest to men on long-term ADT. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers